AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults
|
By HospiMedica International staff writers Posted on 27 Oct 2020 |
|
Image: AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults (Photo courtesy of AstraZeneca)
Early trial results of AstraZeneca Plc’s (Cambridgeshire, England) COVID-19 vaccine candidate suggest that the group most vulnerable to serious illness and death could build immunity as the vaccine has been found to trigger protective antibodies and T-cells in older age groups.
AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). According to a report by The Financial Times, the AstraZeneca-Oxford COVID-19 experimental vaccine triggered protective antibodies and T-cells in older age groups, providing much encouragement to researchers who have been searching for proof of the vaccine’s ability to protect these groups from serious illness or death from the SARS-Cov-2 virus.
Age is now considered as the primary risk factor for COVID-19 severity as the immune system weakens with age. This has raised concerns that a COVID-19 vaccine may fail to protect the very group that generates the least effective response to the SARS-Cov-2 virus. However, early results from immunogenicity blood tests performed on a subset of older participants from trials of the AstraZeneca-Oxford COVID-19 experimental vaccine have shown that the vaccine also triggered protective antibodies and T-cells in older age groups. These results match data released in July that showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55 years, according to The Financial Times. The earlier data had shown that the vaccine induced both antibodies as well as T-cells for at least 56 days.
Researchers are encouraged by the latest development, although positive immunogenicity tests do not guarantee that a COVID-19 vaccine is safe and effective for older people which can be confirmed only after full trial data for the age group has been analyzed.
Related Links:
AstraZeneca
University of Oxford
AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). According to a report by The Financial Times, the AstraZeneca-Oxford COVID-19 experimental vaccine triggered protective antibodies and T-cells in older age groups, providing much encouragement to researchers who have been searching for proof of the vaccine’s ability to protect these groups from serious illness or death from the SARS-Cov-2 virus.
Age is now considered as the primary risk factor for COVID-19 severity as the immune system weakens with age. This has raised concerns that a COVID-19 vaccine may fail to protect the very group that generates the least effective response to the SARS-Cov-2 virus. However, early results from immunogenicity blood tests performed on a subset of older participants from trials of the AstraZeneca-Oxford COVID-19 experimental vaccine have shown that the vaccine also triggered protective antibodies and T-cells in older age groups. These results match data released in July that showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55 years, according to The Financial Times. The earlier data had shown that the vaccine induced both antibodies as well as T-cells for at least 56 days.
Researchers are encouraged by the latest development, although positive immunogenicity tests do not guarantee that a COVID-19 vaccine is safe and effective for older people which can be confirmed only after full trial data for the age group has been analyzed.
Related Links:
AstraZeneca
University of Oxford
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Pressure Guidewire
SavvyWire
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
Light-Based Technology to Measure Brain Blood Flow Could Diagnose Stroke and TBI
Monitoring blood flow in the brain is crucial for diagnosing and treating neurological conditions such as stroke, traumatic brain injury (TBI), and vascular dementia. However, current imaging methods like... Read more
AI Heart Attack Risk Assessment Tool Outperforms Existing Methods
For decades, doctors have relied on standardized scoring systems to assess patients with the most common type of heart attack—non-ST-elevation acute coronary syndrome (NSTE-ACS). The GRACE score, used... Read more
Surgical Techniques
view channel
Minimally Invasive Endoscopic Surgery Improves Severe Stroke Outcomes
Intracerebral hemorrhage, a type of stroke caused by bleeding deep within the brain, remains one of the most challenging neurological emergencies to treat. Accounting for about 15% of all strokes, it carries... Read more
Novel Glue Prevents Complications After Breast Cancer Surgery
Seroma and prolonged lymphorrhea are among the most common complications following axillary lymphadenectomy in breast cancer patients. These postoperative issues can delay recovery and postpone the start... Read more
Patient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more